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http:WHAT THIS PAPER ADDS
Endovascular abdominal aortic aneurysm repair (EVAR) is an effective alternative treatment to open aneurysm
repair and the number of EVAR procedures performed continues to grow worldwide. This less invasive technique
has been established as a safe and effective method of aneurysm exclusion. In this study, we evaluated type 4
and 2 AVPs (AVP4, AVP2) in the prevention of type II endoleaks in visceral and lumbar vessels prior to EVAR.We
show that the use of AVPs prior to EVAR is an effective technique in preventing the development of type II
endoleaks.Objective: We evaluated the feasibility of visceral artery and lumbar artery (LA) embolization using AMPLATZER
vascular plug (AVP) types 4 and 2 (AVP4, AVP2) prior to endovascular aneurysm repair (EVAR) to prevent the
development of a type II endoleak.
Methods: Between January 2008 and April 2010, 45 arteries in 33 male patients were embolized with 44 AVP4
and one AVP2. Artery name and diameter; device number and size; and intervention, ﬂuoroscopy, and
deployment times for each procedure and each device were recorded. Computed tomography (CT) angiography
was performed 2 days and 3, 6, 12, 18, 24, and 36 months after EVAR to conﬁrm successful EVAR and
embolotherapy, exclude endoleaks, and evaluate aneurysm shrinkage.
Results: AVP4 devices were implanted into the inferior mesenteric arteries in 33 cases, lumbar arteries in seven
cases, and pelvic and renal arteries in two cases each. An AVP2 device was inserted into the gluteal artery in one
case. The success rate was 100%, with total occlusion of all target vessels. No endoleaks were found in follow-up
CT angiography.
Conclusion: The use of AVP prior to EVAR is an efﬁcient embolization technique that prevents the development
of type II endoleaks.
 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Endovascular abdominal aortic aneurysm repair (EVAR) is an
effective alternative treatment to open aneurysm repair,1
and the number of EVAR procedures performed continues
to grow worldwide. This less invasive technique has been
established as a safe and effective method of aneurysm
exclusion.2 Incomplete exclusion of the aneurysmal sac
from the circulation, called an endoleak, is the most
frequent complication after EVAR (occurring in 10e45% of
cases),3 and can be associated with aneurysm enlargementh authors contributed equally.
responding author. W. Hundt, Department of Radiology, Philipps
ity Marburg, Baldingerstrasse, 35043 Marburg, Germany.
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//dx.doi.org/10.1016/j.ejvs.2013.10.003and rupture.4 Given the association of type I and III endo-
leaks with adverse clinical outcomes,5 they are considered
treatment failures. In contrast, the importance of type II
endoleaks, which occur at some interval after EVAR in 20e
30% of patients, remains controversial.6
Some working groups7,8 doubt the role of patent side
branches (the inferior mesenteric artery [IMA] and lumbar
artery [LA]) and the type II endoleak in late postoperative
aneurysm shrinkage. This could be disproven by several
studies. Fujita9 reported a reintervention rate of approxi-
mately 26% after EVAR caused by expansion of the aneu-
rysmal sac because of a type II endoleak. Axelrod10 and
Sheehan11 showed a positive effect of preoperative side
branch embolization with greater shrinkage of the aneu-
rysm sac diameter. Different strategies have been proposed
for the prevention and treatment of type II endoleaks, but
no clear consensus exists. Prophylactic intervention can be
performed prior to EVAR (preoperatively) or during EVAR
(intraoperatively), and opinions have varied widely. Some
Table 1. Description of all vessels in the embolized and non-
embolized group.
Embolization group Non-embolization group
Pat.
no.
Number
of vessels
(>2.5 mm)
Number
of vessels
(<2.5 mm)
Pat.
no.
Number
of vessels
(>2.5 mm)
Number
of vessels
(<2.5 mm)
1 4 14 1 d 16
2 1 17 2 d 15
3 1 19 3 d 21
4 1 13 4 d 15
5 1 14 5 d 13
6 1 15 6 d 18
7 1 18 7 d 20
8 1 12 8 d 10
9 2 14 9 d 22
10 2 15 10 d 15
11 3 17 11 d 17
12 5 16 12 d 23
13 1 17 13 d 20
14 2 13 14 d 17
15 1 14 15 d 16
16 1 15 16 d 14
17 1 16 17 d 18
18 1 14 18 d 23
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artery and LA embolization, whereas others intervene only
if an aneurysm grows during EVAR follow-up.
The classical technique is embolization with stainless
steel or platinum coils over a microcatheter using the co-
axial technique.12 This method has some disadvantages,
such as long procedure and ﬂuoroscopy time, risk of coil
dislocation with a non-target embolization or occlusion of
relevant collateral vessels, and high costs because of the
use of the microcatheter and several coils for vessel
occlusion.
AMPLATZER vascular plugs (AVPs), another type of
embolization device, are used in interventional radiology to
occlude arteries and veins of large and middle calibre.13
Indications reported in the literature include hypogastric
and aorto-iliac aneurysms,13 pulmonary14 and renal arte-
riovenous malformations,15 and subclavian aneurysms.16
Their use in EVAR procedures for occluding type II endo-
leaks is limited. It has only recently been addressed in a
small series and a few case reports.17 In this study, we
evaluated AVPs in the prevention of type II endoleaks in
visceral and lumbar vessels prior to EVAR.19 1 15 19 d 13
20 1 13 20 d 16
21 1 17 21 d 19
22 1 15 22 d 14
23 1 16 23 d 18
24 1 13 24 d 15
25 1 15 25 d 14
26 1 16 26 d 16
27 1 18 27 d 18
28 1 14 28 d 13
29 1 16 29 d 18
30 1 14 30 d 12
31 1 15 31 d 17
32 1 16 32 d 15
33 1 14 33 d 14
34 1 16 34 d 18
35 1 17 35 d 20
36 1 15 36 d 14
37 4 17 37 d 18
38 d 16
Total 52 565 d 631METHODS
We retrospectively reviewed the medical records and im-
ages (computed tomography [CT] and digital subtraction
angiography) of patients who underwent endovascular
management prior to EVAR between January 2008 and April
2010.
The average patient age was 69.8 years (range 51e86
years). A pre-procedural assessment included a full clinical
evaluation and standard blood tests. All patients underwent
contrast-enhanced abdominal CT (Somatom Deﬁnition;
Siemens, Erlangen, Germany) using multiplanar recon-
struction. We recorded the names and diameters of all
vessels in both patient groups (with and without emboli-
zation). According to our internal hospital standard, visceral
arteries and LAs with diameters greater than 2.5 mm found
on multiplanar reconstruction of the CT scan were consid-
ered for embolization. We recorded the numbers and sizes
of the devices used to occlude the vessels as well as the
intervention and ﬂuoroscopy times for each procedure and
device.
The coagulation proﬁles of all patients were within
normal limits at procedure time. All of the procedures were
performed under local anesthesia 1e4 weeks prior to
EVAR. Prophylactic antibiotics (1 g sulbactam and 2 g
ampicillin, Unacid 3 g iv; Pﬁzer, NY, USA) were routinely
used. All but one procedure (case 1, use of the AVP2, a 65-
cm/6-F sheath [Destination, Terumo, Japan]) were per-
formed via 4-F femoral access (Brite Tip Sheath; Cordis,
Miami, FL, USA). After catheterization of the target vessel
using an angiographic catheter with a 0.038 inch lumen
(Sidewinder I, Tempo Aqua; Cordis), an AVP (St. Jude
Medical, St. Paul, MN, USA) was introduced into the target
vessel close to the aorta. The plug diameter was 30e50%
larger than the target artery diameter according to themanufacturer’s recommendation. After plug placement
within the artery, a single nonsubtracted image was ob-
tained to document the correct AVP position. If the device
position was satisfactory, it was deployed by rotation of the
delivery wire in a counterclockwise direction. Post-
embolization angiography was performed to conﬁrm plug
position and arterial patency/occlusion. After catheter and
sheath removal, the arterial puncture was closed using
manual compression. To conﬁrm the therapeutic success of
EVAR and exclude any endoleaks, CT angiography was
performed 2e3 days and 3, 6, 12, 18, 24, and 36 months
after EVAR. The patency of the embolized vessels, existence
of endoleaks, and changes in aneurysm size were
evaluated.
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This study included 75 patients who underwent EVAR. In
the 37 patients who received embolization prior to EVAR,
the aortic aneurysms were classiﬁed according to EURO-
STAR classiﬁcation18 as follows: type A, six cases; type B, 21
cases; type C, four cases; and type D, six cases.
These 37 patients had 52 patent visceral arteries and LAs
with diameters greater than 2.5 mm that required emboli-
zation according to our hospital internal standard. In the
embolization group, 617 vessels could be identiﬁed on the
CT scans (Table 1). In three arteries of three patients,
catheterization of a patent IMA with ostial stenosis led to
arterial dissection with spontaneous permanent vessel oc-
clusion. In four other arteries (one IMA and three LAs) in
one patient, embolization was possible only with microcoils
over a microcatheter using the coaxial technique. The
remaining 33 patients with 45 patent aortic side branchesFigure 1. (A), (B) Patent IMA, left colic artery and superior rectal artery.
the IMA oriﬁce, the left colic artery and superior rectal artery are patwere treated with percutaneous transcatheter embolization
using an AVP (44 with AVP type 4, one with AVP type 2).
AVP4 devices were implanted into the IMAs in 33 patients
(Fig. 1), LAs in seven pelvic arteries in two patients, and
accessory renal arteries in two patients, while an AVP2 was
implanted into the gluteal artery in one patient. One pa-
tient with a type IIc aneurysm had a large aneurysm of the
common and internal iliac arteries. The mean aortic aneu-
rysm size was 57.5  9.8 mm (range 45e82 mm) (Fig. 2).
The AVP diameter was approximately 30e50% greater
than that of the blood vessels as recommended by the
manufacturer. The vessel diameters and their corresponding
AVP sizes are shown in Table 2. In each case, the ﬁnal AVP
location was conﬁrmed using angiography prior to its
release. The radioopacity of the device was sufﬁcient and
allowed for easy visualization under ﬂuoroscopy. There were
no incidents of dislodging, non-target embolization, or(C) Implantation of an AVP4. (D) CT after EVAR shows the AVP4 in
ent. No evidence of endoleak.
Figure 2. (A), (B) CT shows aneurysms of the CIA and IIA as well as patent IMA. (C1), (C2) AVP implantation in the IMA. (D1eD4)
Embolization of the iliolumbar artery, superior gluteal artery and pudendal artery. (E), (F) CT after EVAR shows the AVPs in situ. No ev-
idence of endoleak.
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all target vessels were completely occluded prior to the
EVAR procedures. In 12 cases, vessel occlusion could be
observed right after AVP implantation. The occluded vessel
was still patent in 25 cases. However, angiography
conﬁrmed the occlusion of all embolized vessels before
EVAR.
There were no cases of non-target embolization or
ischemic complications caused by embolization.
The intervention time was 10e70 minutes (mean
25  16 minutes) and ﬂuoroscopy time was 3.8e45 mi-
nutes (mean 15  10 minutes). The mean procedure time
per vessel was 12  8 minutes, and the mean ﬂuoroscopy
time per vessel was 9.2  4.5 minutes. Intervention timevaried among cases as a result of various times required to
target the vessels. After a stable catheter position was
obtained within the vessel, the AVP deployment time was
4e8 minutes (mean 6.2  1.1 minutes). On control
angiography after aortic stent implantation, the anasto-
moses between the superior mesenteric artery and the
inferior mesenteric artery were still patent in all cases.
Follow-up imaging was obtained using native and contrast-
enhanced CT.
In the patient group receiving embolization prior to EVAR
implantation, no endoleaks were identiﬁed either directly
after EVAR implantation or in the follow-up period of
30.1  5.3 months. Aneurysmal sac sizes were evaluated on
follow-up CT, and no increases were seen. Aneurysm size
Table 2. Description of the embolized vessels, the used devices, and procedure time.
Pat. no. Vessel no. Vessel name Vessel size
(mm)
AVP size
(mm)
Procedure time
(min)
Deployment time
(min)
Fluoroscopy time
(min)
1 1 IMA 48 7 70 4.2 33
2 Sup. gluteal artery 10.1 16 (AVPII) 6.2
3 Pudendal artery 5.1 7 5.3
4 Iliolumbal artery 4.5 6 6.4
2 5 IMA 4.5 6 15 4.5 8
3 6 IMA 4.5 6 20 6.2 14
4 7 IMA 5.2 7 25 6.8 45
5 8 IMA 4.1 6 26 7.2 12
6 9 IMA 5.6 8 18 5.5 7.3
7 10 IMA 4.2 6 10 6.7 3.8
8 11 IMA 4.2 6 15 7.4 7.2
9 12 IMA 4.6 6 28 4.5 15.2
13 LA 4.8 6 4.0
10 14 IMA 4.6 6 30 6.5 15.5
15 LA 4.2 6 7.2
11 16 IMA 4.1 6 65 5.5 37.5
17 ARA 5.1 7 8.0
18 LA 3.5 5 6.5
12 19 IMA 4.6 7 60 7.2 27.2
20 LA 3.5 5 5.6
21 LA 4.1 6 6.7
22 LA 2.7 4 7.3
23 LA 3.5 5 4.5
13 24 IMA 3.2 4 10 5.2 7.3
14 25 IMA 4.7 7 30 5.6 7.7
26 ARA 4.6 7 6.5
15 27 IMA 4.6 6 15 7.8 16
16 28 IMA 4.8 7 22 6.3 17
17 29 IMA 4.4 6 24 6.4 15
18 30 IMA 3.8 6 20 7.1 9.5
19 31 IMA 4.2 6 15 4.5 8.3
20 32 IMA 4.4 6 16 5.4 12.1
21 33 IMA 4.1 6 12 7.1 13.1
22 34 IMA 4.3 7 15 7.3 10.5
23 35 IMA 4.5 6 21 7.4 11.1
24 36 IMA 3.9 5 18 6.5 10.1
25 37 IMA 4.7 6 16 5.5 9.1
26 38 IMA 4.4 7 22 6.3 12.7
27 39 IMA 4.6 6 14 6.4 11.1
28 40 IMA 4.8 6 13 5.1 8.5
29 41 IMA 4.2 6 12 6.5 9.3
30 42 IMA 4.4 6 14 5.1 13.1
31 43 IMA 4.1 6 13 5.1 11.1
32 44 IMA 4.3 7 14 7.1 8.5
33 45 IMA 4.5 6 17 6.4 9.1
IMA ¼ inferior mesenteric artery; LA ¼ lumbal artery; ARA ¼ accessory renal artery.
32 M. Burbelko et al.remained constant in ﬁve cases and decreased in the other
cases. The mean aortic aneurysm size after EVAR was
53.1  11.5 mm. The mean aortic shrinkage was
11.5  11.3% (Table 3).
In the patient group (38 patients) that received no
embolization prior to EVAR implantation, the aortic aneu-
rysms were classiﬁed according to the EUROSTAR classiﬁ-
cation as follows: type A, seven cases; type B, 22 cases; type
C, four cases; and type D, ﬁve cases. In this non-
embolization group, a total of 631 vessels could be identi-
ﬁed on the CT scan (Table 1).The follow-up period of the patients was 30.2  5.7
months. In nine patients, type II endoleaks were identiﬁed
at the level of the inferior mesenteric artery on the follow-
up scans after 6 or 12 months. In these cases, the aneu-
rysmal sac sizes increased in eight cases and stayed constant
in one case. The average aneurysm size prior to EVAR was
56.3  4.5 mm, and it increased to 63.7  7.8 mm
(13.1  9.7%). These nine patients underwent reinterven-
tion and the inferior mesenteric artery was occluded. In the
other patients without an endoleak, the aneurysm size prior
to EVAR was 62.7  7.7 mm and decreased to
Table 3. Aneurysm type, size prior and post EVAR, change during the follow-up of patients receiving embolization of visceral arteries.
Pat. no. Aneurysm type Aneurysm size prior EVAR (mm) Aneurysm size post EVAR (mm) Follow-up length (mo) Aneurysm change (%)
1 E 58 48 24 17
2 C 60 58 24 3
3 B 55 55 30 0
4 B 60 46 36 23
5 B 51 28 36 45
6 A 70 65 30 7
7 D 53 48 30 9
8 D 54 51 30 6
9 A 69 58 36 16
10 B 55 55 36 0
11 B 58 54 36 7
12 A 45 39 24 13
13 B 56 56 24 0
14 B 82 82 24 0
15 B 66 59 36 11
16 B 56 55 36 2
17 B 59 53 24 10
18 D 55 49 30 11
19 D 59 51 24 14
20 B 72 68 30 6
21 D 68 64 36 6
22 A 55 49 24 12
23 B 59 51 24 15
24 B 62 62 36 0
25 B 72 59 36 22
26 C 55 49 30 11
27 C 59 51 24 14
28 B 72 68 30 6
29 C 68 64 36 6
30 A 55 49 24 12
31 B 59 51 24 15
32 B 62 62 36 0
33 A 72 59 36 22
CIA ¼ common iliac artery; IIA ¼ internal iliac artery.
European Journal of Vascular and Endovascular Surgery Volume 47 Issue 1 p. 28e36 January/2014 3356.2  6.9 mm. The mean aortic shrinkage in this group was
9.4  8.8% (Table 4).DISCUSSION
The advent of endovascular repair of abdominal aortic an-
eurysms using stent grafts was heralded with a great deal of
excitement in both the vascular surgery and interventional
radiology communities. As with any graft, close follow-up
and surveillance are required to maximize long-term suc-
cess. Physical examination and imaging are needed at reg-
ular intervals to conﬁrm that the aneurysmal sac remains
completely isolated from the systemic circulation.19
The incidence of type II endoleaks persisting beyond 6
months is reported to be 3.5e42%.10,20 Endoleaks may
occur beyond a year after EVAR, especially in cases in which
preoperative side branch embolization has not been per-
formed.21 Velazquez22 and Baum23 reported on the trans-
mission of the systemic blood pressure over the patent IMA
into the aneurysmal sac in 50e75% of patients with type II
endoleaks. The role of type II endoleaks after EVAR remains
questionable. Several working groups report the impor-
tance of this endoleak type in post-EVAR morbidity with apotential risk of rupture.24e26 Some authors advocate
intervention on all leaks persisting for more than 6 months
regardless of change in aneurysmal sac size.27 The rationale
for early reintervention includes mitigating the risk of
aneurysm growth and rupture, especially in patients who do
not adhere to close follow-up orders.
Different methods have been proposed for the manage-
ment of type II endoleaks, but a clear consensus has not
been reached. Postoperative treatment is required in up to
26% of type II endoleaks because of expansion of the
aneurysmal sac.9 Laparoscopic ligation of the aortic side
branches28 as well as endovascular treatment such as
retrograde IMA embolization via the superior mesenteric
artery10 or embolization of the LA via translumbar access,29
is feasible but much more complex, time consuming, and
risky compared with preoperative management. Several
studies have examined the effectiveness of preoperative
embolization of the aortic side branches for preventing type
II endoleaks.10,30 Velazquez showed that prophylactic
embolization of the IMA was associated with aneurysm
shrinkage and a lower incidence of type II endoleaks
compared with those in patients who did not undergo
embolization.22 Parry et al.31 demonstrated preoperative
Table 4. Aneurysm type, size prior and post EVAR, change during the follow-up of patients receiving no embolization of visceral arteries.
Pat. no. Aneurysm type Aneurysm size
prior EVAR (mm)
Aneurysm size
post EVAR (mm)
Follow-up
length (mo)
Aneurysm change (%) Endoleak
1 B 59 55 36 7
2 C 68 60 36 12
3 B 55 55 30 0
4 A 59 50 24 15
5 B 53 60 36 13 Type II
6 B 51 65 36 27 Type II
7 B 58 48 36 17
8 B 45 51 30 13
9 D 56 58 24 4
10 A 60 53 30 12
11 B 56 54 36 4
12 B 55 56 24 2 Type II
13 B 60 56 30 7
14 C 66 82 24 24 Type II
15 C 70 61 24 13
16 B 56 55 24 2
17 B 59 51 24 14
18 D 55 55 36 0 Type II
19 D 59 51 36 14
20 C 72 68 30 6
21 A 54 58 24 9 Type II
22 B 69 49 36 29
23 B 55 51 24 7
24 A 62 62 24 0
25 B 72 59 36 18
26 B 55 59 36 8 Type II
27 A 62 51 36 18
28 B 72 68 24 6
29 D 68 64 36 6
30 D 55 49 24 11
31 A 56 51 30 9
32 B 59 62 24 5 Type II
33 B 69 59 24 14
34 C 82 79 36 4
35 B 59 65 36 10 Type II
36 B 72 53 24 26
37 B 66 53 24 20
38 A 59 58 24 2
34 M. Burbelko et al.coil embolization of the sac feeders (the IMA and LA). They
found no type II endoleaks among 13 patients with
occluded side branches at the baseline or 14 patients who
underwent successful IMA or LA embolization. Conversely,
eight of 13 patients with a patent LA developed type II
lumbar endoleaks. The criteria to embolize vessels are
arbitrary. Criteria like a 2.5- or 2.0-mm vessel diameter
without ostial stenosis were established because a large LA
is easier to catheterize and embolize.30 In our study group,
vessels of at least 2.5 mm were embolized.
The intention of our study was to evaluate the use of an
AVP in the preoperative management of endoleaks prior to
EVAR. Our study group included 33 patients and 45
occluded arteries. This is the largest series to report AVP use
in the prevention of the development of type II endoleaks
caused by aortic side branches. It was shown that AVP
implantation within visceral arteries and LAs is very effec-
tive for preventing the development of type II endoleaks. Inour series, all vessels treated with AVPs prior to EVAR were
occluded and none of the patients had endoleaks directly
after implantation or in the follow-up period. In the non-
embolization group, nine patients developed type II endo-
leaks at the level of the inferior mesenteric artery; in four
patients, the aneurysm size increased by more than 10%,
while in one patient, it stayed constant. In these four pa-
tients, reintervention was necessary to occlude the
endoleak.
The advantage of AVP use is that, unlike coil emboliza-
tion, it is possible to occlude the vessel right at the ostium;
thus, any vessel anastomosis remains patent. In all cases in
which the IMA was occluded, the anastomoses between the
superior mesenteric artery and the inferior mesenteric ar-
tery via the arc of Riolan were perfused. Coil embolization
using stainless steel or platinum coils over a microcatheter
in the coaxial technique has the disadvantage of longer
procedure and ﬂuoroscopy times, and a higher risk of coil
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the relevant collateral vessels.
In our study, we showed that the use of an AVP is a very
time-effective method of vessel occlusion. In our series, we
occluded three pelvic arteries for the treatment of a huge
common and internal iliac artery aneurysm, including the
iliolumbar, pudenal, and superior gluteal arteries. In select
cases, an AVP was used to occlude the common or interal
iliac arteries prior to aortoiliac aneurysm repair. Grenon32
reported a series of 20 patients who underwent occlusion
of the common iliac artery or the internal iliac artery prior
to EVAR. The authors concluded that the use of an AVP is a
safe and effective method for occluding the common iliac
artery or the internal iliac artery before or during EVAR and
for preventing endoleak development.
We did not perform an additional cost analysis in our
study; however, close examination of the costs of the
different devices reveals that AVP application is cost-
effective. The costs of the femoral access and catheter
approach are identical to those of coil or AVP embolization.
A coil-depositing microcatheter is required to occlude ves-
sels with coils. A microcatheter costs approximately 300 V,
whereas one coil costs 20e60 V. The total cost of coil
embolization is 360e600 V, whereas that of the AVP is
approximately 300 V without an additional cost for the
microcatheter.
The limitations of this study are that the number of
occluded vessels prior to EVAR was limited to 45 AVPs in
the 33 patients prior to EVAR and that no direct comparison
to coil embolization was performed. This study is the largest
series reporting AVP use prior to EVAR for preventing the
development of type II endoleaks. A large multicenter
prospective study comparing no embolization, coil emboli-
zation, and AVP embolization of the visceral arteries or LAs
would be needed to detect statistically signiﬁcant results.
CONCLUSION
Despite the limitations of our study owing to its retro-
spective nature and limited number of patients, we believe
that preoperative aortic side branch embolization using
AVPs is safe as well as time- and cost-effective for occluding
the visceral arteries and LAs before EVAR. Although there is
still a role for coils as the primary embolic device in small
vessels, our experience suggests that the AVP may be the
method of choice for larger visceral artery and LA occlusion.
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